CERo Therapeutics Holdings Inc
CERO0.095USD
0.000
Close 12/24, 13:00（ET）Quotes delayed by 15 min
113.63KMarket Cap
LossP/E TTM
More Details of CERo Therapeutics Holdings Inc Company
CERo Therapeutics Holdings, Inc. is an immunotherapy company advancing the development of engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body’s full immune repertoire to achieve optimized cancer therapy. This novel cellular immunotherapy platform is designed to redirect patient-derived T cells to eliminate tumors by building in engulfment pathways that employ phagocytic mechanisms to destroy cancer cells, creating what the Company refers to as Chimeric Engulfment Receptor T cells (CER-T). Its lead molecule is CER-1236, an autologous T-cell product that targets a novel tumor antigen, TIM-4 ligand. The Company is initiating clinical trials for its lead product candidate, CER-1236, for hematological malignancies.
CERo Therapeutics Holdings Inc Info
Ticker SymbolCERO
Company nameCERo Therapeutics Holdings Inc
IPO dateOct 06, 2021
CEOEhrlich (Christopher B)
Number of employees- -
Security typeOrdinary Share
Fiscal year-endOct 06
Address201 Haskins Way
CitySOUTH SAN FRANCISCO
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code94080
Phone6504072376
Websitehttps://www.phoenixbiotechacquisitioncorp.com/
Ticker SymbolCERO
IPO dateOct 06, 2021
CEOEhrlich (Christopher B)
Company Executives of CERo Therapeutics Holdings Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Brian G. Atwood
Mr. Brian G. Atwood
Director
Director
24.59K
--
Mr. Christopher B. (Chris) Ehrlich
Mr. Christopher B. (Chris) Ehrlich
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
2.90K
--
Ms. Kathleen D. Laporte
Ms. Kathleen D. Laporte
Independent Director
Independent Director
486.00
--
Dr. Lindsey Rolfe
Dr. Lindsey Rolfe
Independent Director
Independent Director
--
-100.00%
Mr. Andrew (Al Kucharchuk) Albert
Mr. Andrew (Al Kucharchuk) Albert
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Kristen Pierce
Dr. Kristen Pierce
Chief Development Officer
Chief Development Officer
--
--
Mr. Shami J. Patel
Mr. Shami J. Patel
Director
Director
--
-100.00%
Mr. Michael (Mike) Byrnes
Mr. Michael (Mike) Byrnes
Independent Director
Independent Director
--
-100.00%
Name
Name/Position
Position
Shareholding
Change
Mr. Brian G. Atwood
Mr. Brian G. Atwood
Director
Director
24.59K
--
Mr. Christopher B. (Chris) Ehrlich
Mr. Christopher B. (Chris) Ehrlich
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
2.90K
--
Ms. Kathleen D. Laporte
Ms. Kathleen D. Laporte
Independent Director
Independent Director
486.00
--
Dr. Lindsey Rolfe
Dr. Lindsey Rolfe
Independent Director
Independent Director
--
-100.00%
Mr. Andrew (Al Kucharchuk) Albert
Mr. Andrew (Al Kucharchuk) Albert
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Kristen Pierce
Dr. Kristen Pierce
Chief Development Officer
Chief Development Officer
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Tue, Dec 2
Updated: Tue, Dec 2
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Parallel Advisors, LLC
0.57%
Atwood (Brian G)
0.12%
ARCH Venture Partners
0.11%
Susquehanna International Group, LLP
0.05%
Corey (Lawrence)
0.02%
Other
99.14%
Shareholders
Shareholders
Proportion
Parallel Advisors, LLC
0.57%
Atwood (Brian G)
0.12%
ARCH Venture Partners
0.11%
Susquehanna International Group, LLP
0.05%
Corey (Lawrence)
0.02%
Other
99.14%
Shareholder Types
Shareholders
Proportion
Investment Advisor
0.62%
Individual Investor
0.15%
Venture Capital
0.11%
Other
99.12%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
49
157.10K
1.33%
--
2025Q3
51
157.10K
23.30%
-89.79K
2025Q2
52
246.89K
4.22%
+210.62K
2025Q1
55
36.28K
7.90%
+15.86K
2024Q4
87
8.72K
27.17%
-7.46K
2024Q3
109
15.06K
14.25%
+12.16K
2024Q2
108
2.90K
103.80%
+181.00
2024Q1
101
831.00
114.17%
-7.56K
2023Q4
98
417.00
271.82%
+1.00
2023Q3
97
416.00
273.39%
-173.00
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Parallel Advisors, LLC
220.00K
18.25%
+209.00K
+1900.00%
Jun 30, 2025
Atwood (Brian G)
24.59K
2.04%
+1.00
+0.00%
Jun 30, 2025
ARCH Venture Partners
22.39K
1.86%
+21.28K
+1926.15%
Jun 30, 2025
Corey (Lawrence)
4.23K
0.35%
--
--
Dec 10, 2024
Ehrlich (Christopher B)
2.90K
0.24%
+2.00
+0.07%
Jun 30, 2025
Tower Research Capital LLC
684.00
0.06%
+433.00
+172.51%
Jun 30, 2025
FNY Investment Advisers LLC
1.05K
0.09%
+1.04K
+7976.92%
Jun 30, 2025
LaPorte (Kathleen D)
486.00
0.04%
--
--
Jun 30, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Jun 11, 2025
Merger
20→1
Jan 06, 2025
Merger
100→1
Jan 06, 2025
Merger
100→1
Jan 06, 2025
Merger
100→1
Jan 06, 2025
Merger
100→1
Date
Type
Ratio
Jun 11, 2025
Merger
20→1
Jan 06, 2025
Merger
100→1
Jan 06, 2025
Merger
100→1
Jan 06, 2025
Merger
100→1
Jan 06, 2025
Merger
100→1
FAQs
Who are the top five shareholders of CERo Therapeutics Holdings Inc?
The top five shareholders of CERo Therapeutics Holdings Inc are:
Parallel Advisors, LLC holds 220.00K shares, accounting for 18.25% of the total shares.
Atwood (Brian G) holds 24.59K shares, accounting for 2.04% of the total shares.
ARCH Venture Partners holds 22.39K shares, accounting for 1.86% of the total shares.
Corey (Lawrence) holds 4.23K shares, accounting for 0.35% of the total shares.
Ehrlich (Christopher B) holds 2.90K shares, accounting for 0.24% of the total shares.
Parallel Advisors, LLC holds 220.00K shares, accounting for 18.25% of the total shares.
Atwood (Brian G) holds 24.59K shares, accounting for 2.04% of the total shares.
ARCH Venture Partners holds 22.39K shares, accounting for 1.86% of the total shares.
Corey (Lawrence) holds 4.23K shares, accounting for 0.35% of the total shares.
Ehrlich (Christopher B) holds 2.90K shares, accounting for 0.24% of the total shares.
What are the top three shareholder types of CERo Therapeutics Holdings Inc?
The top three shareholder types of CERo Therapeutics Holdings Inc are:
Parallel Advisors, LLC
Atwood (Brian G)
ARCH Venture Partners
Parallel Advisors, LLC
Atwood (Brian G)
ARCH Venture Partners
How many institutions hold shares of CERo Therapeutics Holdings Inc (CERO)?
As of 2025Q4, 49 institutions hold shares of CERo Therapeutics Holdings Inc, with a combined market value of approximately 157.10K, accounting for 1.33% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -21.97%.
What is the biggest source of revenue for CERo Therapeutics Holdings Inc?
In --, the -- business generated the highest revenue for CERo Therapeutics Holdings Inc, amounting to -- and accounting for --% of total revenue.
